Skip to main content
Premium Trial:

Request an Annual Quote

Epistem Collaborating with Sanofi-Aventis on Oncology

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Epistem today announced a three-year collaboration with Sanofi-Aventis US directed at the use of biomarkers to support the drug manufacturer's oncology programs.

Under the terms of the deal, Epistem will provide Sanofi-Aventis its GenetRx biomarker gene expression profiling technology and immunohistochemistry technologies. Epistem is eligible to receive up to $4 million in research support payments, including reimbursement for certain costs, the Manchester, UK-based biotech firm said.

GenetRx extracts mRNA from tissue biopsies, blood, and small amounts of surrogate tissue to measure drug-induced gene expression changes.

The deal is expected to provide Sanofi-Aventis with a biomarker strategy to identify biological responses to drugs in relevant tissues. "The translational nature of this relationship means activities will cover preclinical, ex vivo, and clinical support," Epistem said.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.